S.S. Pirmamedova1, I.I. Antoneeva1,2
1Regional Clinical Oncology Dispensary, Ulyanovsk
2Ulyanovsk State University, Ulyanovsk
Pirmamedova Sabina S. ― doctor of the Department of Oncogynecology of Regional Clinical Oncology Dispensary, SPIN-code 3050-0178, ORCID: 0000-0003-3245-4472
90, September 12 Str., Ulyanovsk, 432017, Russian Federation, tel. (8422) 32-82-62, e-mail: email@example.com
Introduction. Chemotherapy is the basic method for the ovarian cancer (OC) treatment, which is the seventh largest in terms of incidence rates and the fifth leading cause of death from malignant diseases in women. However, treatment with cytotoxic drugs is stopped in every fourth OC patient due to the development of side effects. Preliminary incubation of cytostatic drugs with blood components (autohemochemotherapy (AHCT)) allows to prolong the therapeutic effects of a drug and reduce dose-related toxicity.
The aim of the study was to evaluate the toxicity of OC chemotherapy according to the AP scheme, depending on the method of administration of cytostatic drugs.
Material and methods. 112 primary patients with ovarian cancer in stage III-IV FIGO at the age of 40 to 70 years received neoadjuvant chemotherapy according to the AP scheme: 50 patients in the AHCT mode and 62 patients with traditional solvents (CT). Assessment of the treatment toxicity was performed after the 2nd course of chemotherapy according to a scale ECOG-WHO PS. At the time of treatment starting, all the patients had a ECOG status from 0 to 3 and an life expectancy of at least 6 weeks. It was found that when using the AHCT scheme, the toxicity phenomena: leukopenia, decreased appetite, nausea, cardiotoxicity, neutropenia were less pronounced in comparison with grade III toxicity in the traditional method of chemotherapy administration.
Conclusion. Thus, the method of administration of chemodrugs in the AP scheme affects their toxicity in patients with OC.
Key words: ovarian cancer, toxicity, AP scheme, autohemochemotherapy.